Product Name
DHCR7, siRNA
Full Product Name
DHCR7 siRNA (Human)
Product Synonym Names
D7SR; 7-dehydrocholesterol reductase; 7-DHC reductase; Putative sterol reductase SR-2; Sterol Delta(7)-reductase
Product Gene Name
DHCR7 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9UBM7
Specificity
DHCR7 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human DHCR7 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of DHCR7 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DHCR7 sirna
siRNA to inhibit DHCR7 expression using RNA interference
Applications Tested/Suitable for DHCR7 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for DHCR7. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001157289.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001163817.1
[Other Products]
UniProt Primary Accession #
Q9UBM7
[Other Products]
UniProt Secondary Accession #
O60492; O60717; B2R6Z2[Other Products]
UniProt Related Accession #
Q9UBM7[Other Products]
Molecular Weight
54,489 Da
NCBI Official Full Name
7-dehydrocholesterol reductase
NCBI Official Synonym Full Names
7-dehydrocholesterol reductase
NCBI Official Symbol
DHCR7 [Similar Products]
NCBI Official Synonym Symbols
SLOS
[Similar Products]
NCBI Protein Information
7-dehydrocholesterol reductase
UniProt Protein Name
7-dehydrocholesterol reductase
UniProt Synonym Protein Names
Putative sterol reductase SR-2; Sterol Delta(7)-reductase
Protein Family
Probable 7-dehydrocholesterol reductase
UniProt Gene Name
DHCR7 [Similar Products]
UniProt Synonym Gene Names
D7SR; 7-DHC reductase [Similar Products]
UniProt Entry Name
DHCR7_HUMAN
NCBI Summary for DHCR7
This gene encodes an enzyme that removes the C(7-8) double bond in the B ring of sterols and catalyzes the conversion of 7-dehydrocholesterol to cholesterol. This gene is ubiquitously expressed and its transmembrane protein localizes to the endoplasmic reticulum membrane and nuclear outer membrane. Mutations in this gene cause Smith-Lemli-Opitz syndrome (SLOS); a syndrome that is metabolically characterized by reduced serum cholesterol levels and elevated serum 7-dehydrocholesterol levels and phenotypically characterized by mental retardation, facial dysmorphism, syndactyly of second and third toes, and holoprosencephaly in severe cases to minimal physical abnormalities and near-normal intelligence in mild cases. Alternative splicing results in multiple transcript variants that encode the same protein.[provided by RefSeq, Aug 2009]
UniProt Comments for DHCR7
DHCR7: Production of cholesterol by reduction of C7-C8 double bond of 7-dehydrocholesterol (7-DHC). Defects in DHCR7 are the cause of Smith-Lemli-Opitz syndrome (SLOS); also known as SLO syndrome or RSH syndrome. SLOS is an autosomal recessive frequent inborn disorder of sterol metabolism with characteristic congenital malformations and dysmorphias. All patients suffer from mental retardation. Children with SLOS have elevated serum 7-dehydrocholesterol (7- DHC) levels and low serum cholesterol levels. SLOS occurs in relatively high frequency: approximately 1 in 20,000 to 30,000 births in populations of northern and central European background. Historically, a clinical distinction often was made between classic ('type I') SLOS and the more severely affected ('type II') patients. There is, in reality, a clinical and biochemical continuum from mild to severe SLOS. Belongs to the ERG4/ERG24 family.
Protein type: EC 1.3.1.21; Oxidoreductase; Lipid Metabolism - steroid biosynthesis; Membrane protein, multi-pass; Membrane protein, integral
Chromosomal Location of Human Ortholog: 11q13.4
Cellular Component: nuclear outer membrane; endoplasmic reticulum membrane; membrane; endoplasmic reticulum; integral to membrane
Molecular Function: 7-dehydrocholesterol reductase activity
Biological Process: blood vessel development; regulation of cholesterol biosynthetic process; multicellular organism growth; cell differentiation; cholesterol biosynthetic process; lung development; regulation of cell proliferation; post-embryonic development
Disease: Smith-lemli-opitz Syndrome
Research Articles on DHCR7
1. In this mendelian randomisation study, we generated an allele score (25[OH]D synthesis score) based on variants of genes that affect 25(OH)D synthesis or substrate availability (CYP2R1 and DHCR7)
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
